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This study evaluated the antilipogenic and anti-inﬂammatory eﬀects of Codonopsis lanceolata (C. lanceolata) root extract in mice
with alcohol-induced fatty liver and elucidated its underlying molecular mechanisms. Ethanol was introduced into the liquid diet
by mixing it with distilled water at 5% (wt/v), providing 36% of the energy, for nine weeks. Among the three diﬀerent fractions
prepared from the C. lanceolata root, the C. lanceolata methanol extract (CME) exhibited the most remarkable attenuation of
alcohol-induced fatty liver with respect to various parameters such as hepatic free fatty acid concentration, body weight loss, and
hepaticaccumulationsoftriglycerideandcholesterol.ThehepaticgeneandproteinexpressionlevelswereanalysedviaRT-PCRand
Westernblotting,respectively.CMEfeedingsigniﬁcantlyrestoredtheethanol-induceddownregulationoftheadiponectinreceptor
(adipoR) 1 and of adipoR2, along with their downstream molecules. Furthermore, the study data showed that CME feeding
dramatically reversed ethanol-induced hepatic upregulation of toll-like receptor- (TLR-) mediated signaling cascade molecules.
These results indicate that the beneﬁcial eﬀects of CME against alcoholic fatty livers of mice appear to be with adenosine- and
adiponectin-mediated regulation of hepatic steatosis and TLR-mediated modulation of hepatic proinﬂammatory responses.
1.Introduction
Fatty liver is the most common and earliest response of the
liver to heavy alcohol consumption and may develop into
alcoholic hepatitis and ﬁbrosis [1]. It has been traditionally
held that, during alcohol metabolism, the increase in the
cellular NADH concentration generated by alcohol and alde-
hyde dehydrogenases impairs β-oxidation and tricarboxylic
acid cycle activity in the liver, which in turn leads to severe
FFA overload and enhanced synthesis of triacylglycerol in
the liver [2]. More recently, two transcription factors, the
peroxisome proliferator-activated receptor (PPAR) α and
PPARγ, have been discovered as new mechanisms that con-
trol hepatic fatty acid oxidation and synthesis, respectively
[3, 4]. Ethanol feeding impairs fatty acid catabolism in
the liver partly by blocking PPARα-mediated responses in
C57BL/6J mice. In the meantime, dietary supplementation
of ethanol-fed animals with a PPARα agonist induces the
expression of PPARα target genes and stimulates the rate of
fatty acid β-oxidation, which prevents alcoholic fatty liver
[5]. In contrast to PPARα, hepatic PPARγ contributes to
triglyceride homeostasis, which regulates both triglyceride
clearancefromthecirculationandthelipogenicprogram[6].
Ethanol increases the mRNA expressions of PPARγ and lipid
synthetic enzymes, ATP citrate lyase (ACL), and fatty acid
synthase (FAS) in mice liver [1].
Ethanoliswellknowntostimulateincreasedextracellular
adenosineconcentrationthroughitsactiononthenucleoside
transporter. Ethanol ingestion increases purine release into
the bloodstream and urine in normal volunteers [7–9]a n d
into the extracellular space in liver slices obtained from
mice [10, 11]. Extracellular adenosine regulates various2 Journal of Biomedicine and Biotechnology
physical processes [12], including hepatic ﬁbrosis [10, 11],
ureagenesis [13, 14], and glycogen metabolism [15, 16],
as well as peripheral lipid metabolism [17, 18]. These
physiological eﬀects of adenosine are mediated by a family
of four G-protein-coupled receptors: A1,A 2A,A 2B,a n dA 3
(A1R, A2AR, A2BR, and A3R), each of which has a unique
pharmacological proﬁle, tissue distribution, and eﬀector
coupling [19]. Recently, Peng et al. reported that ethanol-
mediated increases in extracellular adenosine, which act via
adenosineA1RandA2BR,linktheingestionandmetabolism
ofethanoltothedevelopmentofhepaticsteatosis.Thus,they
suggested that targeting adenosine receptors may be eﬀective
in the prevention of alcohol-induced fatty liver [1].
Although fatty liver was thought to be relatively benign,
more recent studies show that fat accumulation makes the
liver more susceptible to injury from other agents such
as drugs and toxins, especially endotoxins [20], which are
believed to be involved in the pathogenesis of alcoholic
hepatitis and ﬁbrosis [21, 22]. Alcohol consumption induces
a state of a “leaky gut” that increases plasma and liver endo-
toxinlevelsandleadstotheproductionofthetumornecrosis
factor α (TNFα)b yK u p ﬀer cells via the toll-like receptor
(TLR) 4, which is known to mediate lipopolysaccharide-
(LPS-) induced signal transduction and to eventually con-
tribute to liver injury [23]. Ethanol-fed mice exhibited an
oxidative stress that was dependent on the upregulation of
multiple TLRs (TLR1, 2, 4, 6, 7, 8, and 9) in the liver and was
sensitive to liver inﬂammation induced by multiple bacterial
products recognized by the TLRs [24].
Codonopsis lanceolata (C. lanceolata), which belongs to
the Campanulaceae family, is a perennial herb that grows
naturally in moist places in woods, low mountains, and
hills [25]. It is commonly found in East Asia, particularly
in China [25]. C. lanceolata, which is composed of various
active components including tannins, saponins, polyphe-
nolics, alkaloids, essential oils, and steroids, has long been
prescribed in traditional folk medicine in Korea, Japan,
and China [26–28]. The dried roots of C. lanceolata have
been used as a traditional remedy for lung inﬂammatory
diseases such as asthma, tonsillitis, and pharyngitis. The total
methanol extracts of the fresh leaves or roots of C. lanceolata
signiﬁcantly suppress the production of TNFα and nitric
oxide,theexpressionofinterleukin(IL)-3andIL-6,andLPS-
mediated phagocytic uptake in RAW 264.7 cells [28]. In a rat
model, C. lanceolata water extract signiﬁcantly improved the
hepatic accumulation of triglyceride and cholesterol induced
by a high-fat diet [29]. Although the lipid-lowering eﬀect
of C. lanceolata extract has been demonstrated in a rodent
model with diet-induced obesity, the protective eﬀects of
this plant against alcoholic fatty liver diseases have not yet
been explored. In this study, the potent bioactivities of the C.
lanceolata methanol extract that can be used as natural com-
pound or pharmaceutical supplements for the prevention
and/or treatment of alcoholic fatty liver were demonstrated.
ThemechanismsbywhichtheC.lanceolatamethanolextract
performs its antilipogenic and anti-inﬂammatory actions
were investigated in the hepatic tissues of mice with chronic
ethanol consumption.
2.MaterialsandMethods
2.1. Preparation of C. lanceolata Extract. C. lanceolata,w h i c h
is cultivated in Gangwon-do, Korea, was purchased and
freeze dried. Freshly dried material was ground into ﬁne
powder in an electric grinder and stored in dessicator. 200g
plantpowderwasreﬂuxedwith95%methylalcohol(MeOH)
inaroundbottomﬂaskonawaterbathfor3h.CrudeMeOH
extract was ﬁltered out and evaporated to dryness for the
preparation of the C. lanceolata methanol extract (CME).
The residual methanol extract was again reﬂuxed with
distilled water for 5h and ﬁltered. The ﬁltrate, thus obtained,
was again added with ethanol at the ratio of 1:4 and then
stirred for 1h at 4◦C. Following their centrifugation at
5,000×gfor30minat4 ◦C,thesupernatantwasconcentrated
in a rotary vacuum evaporator and freeze dried for the
preparation of the C. lanceolata ethanol supernatant (CES),
and the pellets were air dried and freeze dried for the
preparation of the C. lanceolata ethanol precipitate (CEP).
The yields of these three extracts were 3.84% (CME), 5.05%
(CES), and 3.30% (CEP) of the wet C. lanceolata root,
respectively.
2.2. Animals and Diets. Speciﬁc pathogen-free male
C57BL/6N mice (eight weeks old) were purchased (Orient,
Gyeonggi-do, Korea) and acclimatized to the authors’animal
facility for one week prior to the experimentation. The mice
were kept individually in sterilized animal quarters with
controlled temperature (at 21 ± 2◦C) and humidity (at
50 ± 5%) and with 12h light and dark cycles and were
allowed free access to standard chow and tap water during
the acclimatization period. The animals were then randomly
divided into ﬁve groups (n = 8) and fed the normal diet
(ND), the ethanol diet (ED), the CME-supplemented
ethanol diet (MED), the CES-supplemented ethanol diet
(ESD), or the CEP-supplemented ethanol diet (EPD) for
nineweeks.ThemiceintheEDgroupconsumedaliquiddiet
wherein ethanol provided 36% of the energy, as described
by Lieber et al. [30]. Ethanol was introduced into the diet
by gradually mixing it with distilled water, from 0% (wt/v)
to 5% (wt/v), over a one-week period for adaptation, and
was provided at 5% (wt/v) for the next eight weeks. The ND
mice received the same diet but with isocaloric amounts of
dextrin-maltose instead of ethanol, and the MED, ESD, and
EPD mice were fed the ethanol diet that contained 0.091%
(wt/v) CME, CES, and CEP, respectively. The compositions
of the experimental diets are given in Table 1.T h eN D ,M E D ,
DES, and EPD mice were pair fed so that their consumption
would be isocalorically equivalent to the consumption on
the previous day of the ED mice that were individually
paired with them. The animals that were used in this study
were treated in accordance with the Guide for the Care and
Use of Laboratory Animals (Institute of Laboratory Animal
Resources, Commission on Life Sciences, National Research
Council, 1996), as approved by the Institutional Animal
Care and Use Committee of Yonsei University.
2.3. Histological Examination. The liver tissue specimens
were ﬁxed in 10% buﬀered formalin and embedded inJournal of Biomedicine and Biotechnology 3
Table 1: Compositions of experimental diets.
Ingredient ND ED MED ESD EPD
g/L
Casein 41.4 41.40 41.40 41.40 41.40
L-cystine 0.50 0.50 0.50 0.50 0.50
DL-
methionine 0.30 0.30 0.30 0.30 0.30
Corn oil 8.50 8.50 8.50 8.50 8.50
Olive oil 28.40 28.40 28.40 28.40 28.40
Saﬄower oil 2.70 2.70 2.70 2.70 2.70
Dextrine-
maltose1 115.20 25.60 25.60 25.60 25.60
Vitamin mix
(AIN-76G)2 2.50 2.50 2.50 2.50 2.50
Mineral mix
(AIN-76G)3 8.75 8.75 8.75 8.75 8.75
Choline
bitartrate 0.53 0.53 0.53 0.53 0.53
Cellulose 10.00 10.00 10.00 10.00 10.00
Xanthan gum 3.00 3.00 3.00 3.00 3.00
Ethanol 50.00 50.00 50.00 50.00
CME 0.91
CES 0.91
CEP 0.91
Water 778.22 817.82 816.91 816.91 816.91
Total 1000 1000 1000 1000 1000
1Dextrin: maltose = 80:20.
2Vitamin mixture (g/kg mix); thiamin · HCl 0.6; riboﬂavin 0.6; nicoti-
namide 25; pyridoxine· HCl 0.7; nicotinic acid 3; D-calcium pantothen-
ate 1.6; folic acid 0.2; D-biotin 0.02; cyanocobalamin (vitamin B12)
0.001; retinyl palmitate (250,000 IU/gm) 1.6; DL-α-tocopherol acetate
(250IU/gm) 20; cholecalciferol (vitamin D3) 0.25; menaquinone (vitamin
K2) 0.05; sucrose, ﬁnely powdered 972.9.
3AIN-76 Mineral mixture (g/kg mix); CaHPO4 500; NaCl 74; K2H6O7H2O
220; K2SO452; MgO 24; MnCO3 3.57; Fe (C6H5O7) · 6H2O 6; ZnCO3 1.6;
CuCO3 0.3; KIO3 0.01; Na2SeO3· 5H2O 0.01; CrK (SO4)2 0.55; sucrose,
ﬁnely powdered 118.
paraﬃn, cut at thicknesses of 5μm, and later stained
with hematoxylin and eosin (H&E) for the histological
examination of fat droplets.
2.4. Biochemical Assays. The serum concentrations of total
cholesterol, HDL cholesterol, triglyceride, and free fatty
acid were determined using commercial kits (BioClinical
System, Gyeonggi-do, Korea). Hepatic lipids were extracted
through the procedure developed by Folch et al. [31], using
a chloroform-methanol mixture (2:1, v/v). The dried lipid
residues were dissolved in 1mL of ethanol for the cholesterol
and triglyceride measurements. The hepatic cholesterol,
triglyceride, and free fatty acid concentrations were analyzed
using the same enzymatic kit that was used in the serum
analyses. The serum alanine aminotransferase (ALT) and
aspartate aminotransferase (AST) activities were measured
using commercial reagents (Bayer, USA).
2.5. Isolation of Total RNA and Semiquantitative RT-PCR.
The total RNA was extracted from the liver using a Trizol
reagent (Invitrogen, USA) and was reverse transcribed
using the Superscript II kit (Invitrogen, USA) according
to the manufacturer’s recommendations. The primers for
the PCR analysis were synthesized by Bioneer (Korea).
The forward (F) and reverse (R) primer sequences for
the genes that were involved in the experiment are shown
in the Supplementary Material available online at doi:
10.1155/2012/141395. The PCR for the glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) was performed on each
sample as an internal positive-control standard. The number
of cycles and the annealing temperature were optimized for
each primer pair. Ampliﬁcation of the GAPDH, A1R, A2AR,
A 2 B R ,A 3 R ,P P A R α, carnitine palmitoyltransferase (CPT-1),
microsomal triglyceride transfer protein (MTP), long-chain
acyl-CoA dehydrogenase (LCAD), medium-chain acyl-CoA
dehydrogenase (MCAD), PPARγ, retinoid X receptor (RXR),
CCAAT-enhancer-binding protein-α (C/EBPα), lipoprotein
lipase(LPL),adipocyteprotein2orfattyacidbindingprotein
4 (aP2), FAS, TLRs, LPS binding protein (LBP), cluster of
diﬀerentiation 14 (CD14), myeloid diﬀerentiation primary
response gene 88 (MyD88), myelin and lymphocyte pro-
tein (MAL), TLR adaptor molecule (TRIF), TNF-receptor-
associated factor 6 (TRAF6), interferon regulatory factors
(IRFs), nuclear factor kappa B-p50 (p50), p65, interferon α
(IFNα), IFNβ, IL-12-p40, chemokine (C-X-C motif) ligand
2 (CXCL2), adiponectin receptor 1 (adipoR1), adipoR2,
silent-mating-type information regulation 2 homolog 1
(SIRT1), peroxisome proliferative activated receptor gamma
coactivator 1 alpha (PGC1α), and sterol regulatory element
binding transcription factor 1 (SREBP-1c) was initiated via
5min of denaturation at 94◦C for 1cycle, followed by 30
or 35cycles at 94◦C for 30s, 55 or 60◦C for 30s, and
72◦C for 1min and via 10min of incubation at 72◦C. The
sequencesoftheprimerpairsandPCRconditions(annealing
temperatures, cycles, and product sizes) that were used in
the RT-PCR experiments are shown in the Supplementary
Material. The PCR products were then separated in a 2%
agarose gel and visualized in a gel documentation system
(Alpha Innotech, USA). The intensity of the bands on the
gels was converted into a digital image with a gel analyzer.
2.6. Western Blot Analysis. For the Western blot studies, pro-
tein extracts were obtained from the mice livers using a com-
mercial lysis buﬀer (Intron, USA) that contained a protease
inhibitor cocktail (Roche, USA). The protein concentrations
were determined with the Bio-rad protein assay kit (Bio-
rad, USA). The Western blot analysis was performed with
antibodiesthatwerespeciﬁctoAMP-activatedproteinkinase
(AMPK), phospho-AMPK (Thr 72), Acetyl-CoA carboxylase
(ACC), phospho-ACC (Ser 79) (Cell Signaling, USA), and
β-actin (Santa Cruz, USA). After the SDS-PAGE at 10%
acrylamide concentrations, the proteins were transferred to
thenitrocellulosemembrane,blockedwith5%skimmilkina
Tris-buﬀered saline/Tween buﬀer (10mM Tris-HCl, pH 7.5,
150mM NaCl, and 0.05% Tween 20), and incubated with
appropriate antibodies overnight. The blots were washed
extensively, incubated with a horseradish-peroxidase-linked4 Journal of Biomedicine and Biotechnology
Table 2: Body weight gain and serum biochemistries of mice fed experimental diets.
ND ED MED ESD EPD
Body weight gain (g/9 weeks) 10.9 ±0.4a1 5.3 ± 0.8c 7.6 ±0.7b 7.5 ±0.6b 4.6 ±0.6c
Triglyceride (mmol/L) 0.78 ±0.01b 0.81±0.02ab 0.74 ±0.03b 0.86 ±0.02a 0.75 ±0.02b
Total cholesterol (mmol/L) 2.17 ±0.19b 2.15 ±0.13b 1.96 ±0.13b 2.65 ±0.18a 2.23 ±0.10a
HDL cholesterol (mmol/L) 0.88 ±0.04b 1.10 ±0.10a 1.17 ±0.06a 1.04±0.08ab 1.09±0.06ab
VLDL + LDL cholesterol (mmol/L)2 1.29±0.19ab 1.06 ±0.15b 0.79 ±0.12b 1.60 ±0.21a 1.14±0.15ab
Atherogenic index3 1.52 ±0.25a 1.07±0.21ab 0.70 ±0.13b 1.65 ±0.21a 1.12±0.10ab
Free fatty acid (μEq/L) 808 ±31b 990 ±27a 848 ±36b 1074 ±52a 883 ±32b
ALT (IU/ml) 6.87 ±0.42c 21.2 ±0.89a 17.5 ±0.53b 21.3 ±0.78a 21.2 ±1.04a
AST (IU/ml) 17.63±1.63b 22.3 ±2.05a 17.4 ±1.05b 24.6 ±1.04a 24.9 ±0.98a
1Each value is expressed as mean ± SEM (n = 8). Means with diﬀerent letters within a row are signiﬁcantly diﬀerent (P<0.05).
2VLDL + LDL cholesterol (mmol/L) = Total cholesterol − HDL cholesterol.
3Atherogenic index = (Total cholesterol − HDL cholesterol)/ HDL cholesterol.
anti-rabbit or -mouse Ig (Santa Cruz, USA), and washed
again. The detection was carried out with the ECL Western
blotting kit (Animal Genetics, Korea), after which the blots
were exposed to an X-ray ﬁlm (Agfa, Belgium).
2.7. Statistical Analysis. The results of the body weight gain,
liver weight, and serum and hepatic biochemistries were
expressed as the mean values ± SEM of the eight mice in
each group. The results of the semiquantitative RT-PCR and
Western blot were expressed as the mean values ± SEM of
the three independent experiments in which the RNA and
protein samples from the eight mice were used, respectively.
The analysis of the variance (ANOVA) and the Duncan’s
multiple range method were used to compare signiﬁcant
diﬀerences among the groups. The level of signiﬁcance was
set at P<0.05 for all the statistical tests.
3. Results
3.1. Body Weight Gain and Blood Biochemistries. The nine-
week body weight gain of the mice in the ED group was
51% lower than the value for the pair fed ND mice. The
animals that were fed the MED (43% greater) or the ESD
(41% greater) exhibited signiﬁcantly greater body weight
gains than the ED mice, whereas the mice that were fed
the EPD did not recover the weight they lost from ethanol
consumption (Table 2).
Compared to the values for the ED mice, the mice that
were fed the MED exhibited signiﬁcantly lower levels of
serum FFA (17% reduction) and lower activities of serum
ALT (17% reduction) and AST (22% reduction). They
also demonstrated a tendency towards decreasing serum
triglyceride, total cholesterol, VLDL + LDL cholesterol, and
atherogenic indices, albeit at statistically insigniﬁcant levels
than those for the mice that were fed the ED. In contrast,
the ESD or EPD failed to improve both the lipid levels and
enzyme activities in the blood of the mice with chronic
ethanol consumption (Table 2).
3.2. Liver Weight and Hepatic Lipid Levels. Histological
analysis of the livers with H&E staining revealed prominent
lipid accumulation in the livers of the ED fed mice whereas
lipid droplets were rare in the livers of the MED, ESD,
and EPD-fed mice (Figure 1). ED feeding of the mice for
nine weeks resulted in more signiﬁcant increases in the
relative weight of their livers (by 8%) and in the hepatic
levels of their triglycerides (43% increase), cholesterol (36%
increase), and FFA (52% increase) than in the ND group
(Figure 1). The MED or ESD signiﬁcantly improved the
ethanol-induced enlargement of the liver (the relative liver
w e i g h tw a s7 %o r6 %l o w e r ,r e s p . ) .T h eM E D ,E S D ,o rE P D
signiﬁcantlyreversedtheethanol-inducedhepaticaccumula-
tions of triglycerides (18%, 11%, and 18% reductions, resp.),
cholesterol (22%, 12%, and 18% reductions, resp.), and FFA
(29%, 14%, and 22% reductions, resp.). The triglyceride
and cholesterol levels in the liver were lowest after the
MED consumption among the diets that were supplemented
with diﬀerent fractions of the C. lanceolata root, but the
diﬀerencesbetweenthedietswerenotstatisticallysigniﬁcant.
The MED group exhibited the most prominent and the most
signiﬁcant improvement in the reduction of the hepatic FFA
accumulation, better than did the ESD and EPD groups (P<
0.05) (Figure 1).
3.3. Regulation of Adenosine Receptor-Mediated Signaling
Molecules. MED feeding signiﬁcantly reversed the ethanol-
induced upregulation of the A1R and A2BR genes in
the livers of the mice and restored the ethanol-induced
downregulation of the PPARα,C P T - 1 ,M T P ,L C A D ,a n d
MCAD genes in the livers of the mice (Figures 2(a) and
2(b)). The supplementation of the ethanol diet with CME
signiﬁcantly blunted the upregulation of these transcription
factors and of their target genes due to ethanol.
3.4. Regulation of Adiponectin Receptor-Mediated Signaling
Molecules. Chronic ethanol ingestion led to more signiﬁcant
decreases in the hepatic expression of the adipoR1 and
adipoR2 genes than in the ND mice, and MED feeding
signiﬁcantly restored these ethanol-induced changes in the
adiponectin receptor genes. Similarly, the MED feeding
signiﬁcantly reversed the marked decreases in the mRNA
levels of the hepatic SIRT1 and PGC1α, which were inducedJournal of Biomedicine and Biotechnology 5
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Figure 1: Codonopsis lanceolata extracts substantially reduces alcohol-induced liver steatosis. (a) Hematoxylin and eosin-stained sections of
representative liver samples of the treated groups (100×). (b) Changes in the liver-to-body weight ratio. Hepatic triglyceride, free fatty acid,
and cholesterol levels are shown in (c, d, and e). The data are expressed as means ± SEM (n = 8). a,b,c,dMeans not sharing a common letter
are signiﬁcantly diﬀerent (P<0.05).
by ethanol feeding. In addition, the MED eﬃciently coun-
teracted the ethanol-induced upregulation of the SREBP-
1c gene (higher 57% reduction than in the ED mice,
P<0.05) (Figure 3). The MED signiﬁcantly blunted the
downregulation of the phospho-AMPK/total AMPK (146%
increase) ratio and of the phospho-ACC/total ACC ratio
(700% increase), which were caused by chronic ethanol
ingestion, in the livers of the mice (Figures 3(b) and 3(c)).
3.5. Regulation of TLRs-Mediated Signaling Molecules. The
hepatic expression of the TLR mRNAs was measured after
nine weeks of ethanol exposure. More signiﬁcant increases
in the TLR1, TLR2, TLR3, TLR4, TLR6, TLR7, TLR8, TLR9,
TLR12, and TLR13 mRNA levels were observed in the livers
of the ethanol-fed control mice than of the pair fed ND
mice. The MED signiﬁcantly alleviated the ethanol-induced
upregulationofthehepaticTLR1,TLR2,TLR4,TLR6,TLR7,
TLR8, TLR9, TLR12, and TLR13 gene expressions. The
hepatic TLR3, which was upregulated by the ethanol feeding,
and the hepatic TLR5, which was unaﬀected by the ethanol
feeding, did not respond to the MED feeding (Figure 4).
After endotoxin bound itself to the LPS-binding protein
(LBP), it associates in the portal blood with the CD14 prior
toitsbindingtoTLR4andalltheTLRsthatwererecruitedby
MyD88, MAL, TRIF, and TRAF6 for their proinﬂammatory
signaling. The mRNA levels of the LBP and CD14, as well as
of the adaptor molecules of the TLRs (MyD88, MAL, TRIF,
and TRAF6), all more signiﬁcantly increased in the livers of
the ED mice than of the ND mice, whereas the MED feeding
led to more signiﬁcant decreases in the hepatic mRNA levels
of the LBP, CD14, MyD88, MAL, TRIF, and TRAF6 than in
the ED mice (Figure 5(a)). Among the extremely signiﬁcant
recent discoveries on TLR signaling is that the MyD88-
dependent pathway also activates some IRFs, such as IRF1,
3, 5, and 7. In this study, the mRNA levels of the IRF1,
3, 5, and 7 genes more signiﬁcantly increased in the livers
of the ED mice than of the ND mice and these ethanol-
induced upregulations of the hepatic IRFs were signiﬁcantly
reversed by the MED feeding (Figure 5(b)). The RT-PCR
analysis of the hepatic mRNAs of NFκB (p50 and p65)
and of its target cytokine genes such as TNFα,I L - 6 ,I F N α,
IFNβ,IL-12-p40,andCXCL2wasperformednext.TheMED
feeding signiﬁcantly downregulated the expressions of the
p50, p65, TNFα,I L - 6 ,I F N α,I F N β, IL-12-p40, and CXCL2
genes compared to the ED mice (Figure 5(c)).
4. Discussion
The authors’ previous study showed that the supplementa-
tion of the Lieber-DeCarli ethanol diet with C. lanceolata6 Journal of Biomedicine and Biotechnology
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Figure 2: mRNA expression of the hepatic genes that are involved in fatty acid oxidation or adipogenesis. The left panel shows an RT-PCR
analysis of (a) A1R, A2AR, A2BR, and A3R (b) PPARα, CPT-1, MTP, LCAD, and MCAD and (c) PPARγ,R X R ,C / E B P α, LPL, aP2, and
FAS expression. The images show the representative agarose gel electrophoresis of the PCR products. The right panel shows the relative
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and FAS levels. The data were normalized to the GAPDH levels, and all the expression levels that are displayed are relative to the ND. The
results that are shown represent the means ± SEM of the three independent experiments in which RNA samples from eight mice were used.
a,b,cMeans not sharing a common letter are signiﬁcantly diﬀerent (P<0.05).
water extract (5mg/L of a liquid diet) showed a signiﬁcant
improvementintheamountofweightthatwasgainedandin
the hepatic lipid levels (in the press). In this study, the eﬀects
of three diﬀerent fractions of C. lanceolata roots, which
were prepared using diﬀerent solvents, on the protection
from alcoholic fatty liver were tested. Several studies have
demonstrated that the protective eﬀects of various plant
extracts from alcoholic liver injury in animals, such as
of fenugreek seed (Trigonella foenum fraecum) methanol
extract [32], and hot water extracts of avaram leaves (Cassia
auriculata)[ 33]a n dg r e e nt e a( Camellia sinensis)[ 34]w e r e
manifested at dosages of between 200 and 500mg/kg of body
weight. Based on these studies, C. lanceolata root fractions
were added to a liquid diet at 0.091% (wt/v), which is
equivalent to a daily intake of 300mg/kg of body weight,
a s s u m i n gt h a tam o u s ew e i g h s3 0ga n dc o n s u m e s1 0m lo f
a liquid diet per day.
Among the three diﬀerent fractions that were prepared
fromtheC.lanceolataroot,CMEexhibitedthemostremark-
able attenuation of alcohol-induced fatty liver in terms of
various parameters. For example, CME more signiﬁcantly
reduced the serum ALT and AST activities and the hepatic
FFA concentration in the mice that were fed ethanol than did
CES or CEP. Besides, alcohol-induced body weight loss andJournal of Biomedicine and Biotechnology 7
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Figure 3: Alcohol-induced liver adiponectin receptors and involved genes in mRNA or protein expression. (a) The left panel shows the
results of the RT-PCR analysis of adipoR1, adipoR2, SRIT1, PGC1α, and SREBP-1c expressions. The images show the representative agarose
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f r o me i g h tm i c ew e r eu s e d .a, b, cMeans not sharing a common letter are signiﬁcantly diﬀerent (P<0.05).
hepatic accumulations of triglycerides and cholesterol more
signiﬁcantly improved in mice that were supplemented with
CME than in animals that were supplemented with ESD or
EPD, although the diﬀerence was statistically insigniﬁcant.
Therefore, CME appeared to be the most potent, among
the fractions that were obtained from the C. lanceolata
root, in protecting animals from alcohol-induced hepatic
accumulation of lipids. Further investigated were the under-
lying mechanisms of CME against hepatic steatosis induced
by chronic ethanol administration. The ethanol-induced8 Journal of Biomedicine and Biotechnology
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elevation of the plasma HDL cholesterol concentration,
as observed in the current study, has been suggested as
a cardioprotective response in animals chronically loaded
with ethanol [35]. The elevated HDL concentration and the
reduced LDL concentration, which are characteristic of the
lipoprotein pattern in chronic alcoholics, could well explain
the reduced risk of coronary heart disease in alcoholics [36].
Inthispresentstudy,themRNAexpressionofthehepatic
A2BR and A1R was markedly elevated by chronic ethanol
feeding. Furthermore, the expression of PPARα a n do fi t s
target genes, such as CPT-1, MTP, LCAD, and MCAD, all
signiﬁcantly decreased, whereas the expression of PPARγ
and of its target genes, such as RXR, C/EBP, LPL, aP2, and
FAS, all signiﬁcantly increased in the livers of the ethanol-
fed ED mice than of the ND mice (Figure 6). These results
are in accordance with recent ﬁndings from experiments
with mice that adenosine generated by ethanol metabolism
plays an important role in ethanol-induced hepatic steatosis
via A1R and A2BR, which leads to the upregulation of
PPARγ and the downregulation of PPARα,r e s p e c t i v e l y[ 1].
ItwasobservedthatCMEsupplementationreversedethanol-
induced elevation of the expressions of A2BR, A1R, PPARγ,
and their target genes in the liver tissues of mice. These
results suggest that CME ameliorates hepatic steatosis in
mice, at least partly by modulating adenosine-receptor-
mediated signaling molecules that are responsible for fatty
acid oxidation and lipogenesis.
Adiponectin stimulates hepatic AMPK, which, in turn,
phosphorylates ACC on Ser-79 and attenuates ACC activity.
Inhibition of ACC directly reduces lipid synthesis and
indirectly enhances fatty acid oxidation by blocking the
production of malonyl-CoA, an allosteric inhibitor of CPT-
1[ 37]. Activation of AMPK by adiponectin in the liver also
leads to decreased mRNA and protein expression of SREBP-
1c[38–41],whichresultsindecreasedhepaticlipidsynthesis.
Adiponectin is also known to stimulate the activities of both
PGC1α and PPARα, which mainly control the transcription
of a panel of genes that encode fatty acid oxidation enzymes
[42, 43]. As a result, adiponectin-mediated AMPK activation
favors lipid catabolism and opposes lipid deposition in the
liver [44–49]. Chronic ethanol administration is known to
signiﬁcantly decrease the plasma adiponectin level in mice
[50]. In this study, more signiﬁcant decreases in the mRNA
levels of AdipoR1 and AdipoR2 were observed in the livers
of the ED mice than of the pair fed ND mice. These alcohol-
inducedreductionsinthehepaticAdipoRsexpressionappear
to have been associated with the subsequent decreases in the
phosphorylation of AMPK and ACC as their phosphoryla-
tions in the liver more signiﬁcantly decreased in the ED mice
than in the ND mice (Figure 6).
Besides, the hepatic mRNA levels of SIRT1, PGC1α,
SREBP-1c, PPARα, and CPT1 were also more signiﬁcantly
reduced in the ED mice than in the ND mice (Figure 6).
SIRT1 has been gaining recognition as one of the critical
agents in the mediation of adiponectin signaling to AMPK
[37], which is the central mechanism in the regulation of
lipid metabolism [52–55]. Although PGC1α was initially
identiﬁed as a coactivator of PPARγ, it has subsequentlyJournal of Biomedicine and Biotechnology 9
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Figure 5: mRNA expressions of the hepatic genes that were involved in the inﬂammation. The left panel shows the results of the RT-PCR
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been shown to serve as a cofactor of several other tran-
scription factors, including PPARα [56, 57]. Treatment with
adiponectin restored the ethanol-inhibited PGC1α/PPARα
activity in cultured hepatic cells and in animal livers, which
suggests that the stimulation of adiponectin-SIRT1 signaling
may serve as an eﬀective therapeutic strategy for treating or
preventing human alcoholic fatty liver [38–40]. In this study,
CMEsigniﬁcantlyrestoredtheethanol-induceddownregula-
tion of adiponectin-mediated signaling molecules, including
adipoR1, adipoR2, pAMPK/AMPK, pACC/ACC, SIRT1, and
PGC1α, which led to increased fatty acid oxidation and
decreased lipogenesis in the livers of the mice.
It was recently shown that innate immune cells recognize
conserved pathogen-associated molecular patterns through
pattern recognition receptors, among which the family of
TLRsoccupiesanimportantplace[24].LBP,whichispresent
in normal serum, recognizes and binds to LPS with high
aﬃnitythroughitslipidmoiety[58,59].LPS-LBPcomplexes10 Journal of Biomedicine and Biotechnology
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Figure 6: Schematic diagram illustrating the antilipogenic and anti-inﬂammatory activities of Codonopsis lanceolata in the liver of mice with
chronic ethanol consumption. Adapted from Peng [1], You and Rogers [37, 51]. The arrows denote the direction of the responses to altered
conditions with ED feeding relative to ND feeding (gray arrows), and with MED feeding relative to ED feeding (black arrows).
then activate cells through the second glycoprotein, the
membrane-bound CD14, to produce inﬂammatory medi-
ators [60–62] in the presence of only a functional TLR4
[63]. Although LPS was not detected in the blood, more
signiﬁcant increases in the mRNA levels of LBP and CD14
were observed in the livers of the ED mice than of the
ND mice (Figure 6). TLRs have a TIR domain that initiates
the signaling cascade through TIR adapters, such as MyD88
[64], Mal [65, 66], and TRIF, which interact with TRAF6,
the downstream adaptor. TRAF6 activates the IRFs, which
leads to NF-κB activation and induction of the expressions
of proinﬂammatory cytokines [67], such as of TNFα,I L - 6 ,
IFNα,a n dI F N β.
Itwasdemonstratedthatchronicethanolfeedinginduces
hepatic steatosis and clear upregulation of TLR1, 2, 3, 4, 6,
7, 8, 9, 12, and 13 in the liver. These ﬁndings are supported
by previous reports that ethanol-fed mice exhibited hepatic
inﬂammation that was dependent on the upregulation of
multiple TLRs in the liver [24]. The expressions of the
MyD88, MAL, TRIF, TRAF6, IRF1, 3, 5, and 7 genes,
along with the mRNA levels of NFκB and proinﬂammatory
cytokines, were all more signiﬁcantly elevated in the livers of
theEDmicethanoftheNDmice(Figure 6).Theseresultsare
also in accordance with previous observations that MyD88 is
required for the development of ﬁbrosis [68], a predisposing
condition for hepatocellular cancer development, and that
IRF7 expression more signiﬁcantly increased in the livers of
alcohol-fed MyD88-deﬁcient mice than of pair fed control
mice [69]. These results suggest that chronic ethanol intake
may activate TLR-mediated proinﬂammatory signaling cas-
cades. The study data show that these hepatic inductions
of TLR-mediated signaling cascade molecules, which involve
both MyD88-dependent and -independent pathways, along
with their target proinﬂammatory cytokine genes, such as
TNFα,I L - 6 ,I F N α,I F N β, IL-12-p40, and CSCL2, due to
ethanol feeding were all dramatically reversed with CME
supplementation.
Taken together, these beneﬁcial eﬀects of CME against
alcoholic fatty livers in mice appear to have occurred
with adenosine- and adiponectin-mediated regulations of
hepatic steatosis and TLR-mediated modulation of hepatic
proinﬂammatory responses, since ethanol-induced changes
in the expression of the molecules that are involved in these
three signaling pathways were all signiﬁcantly reversed with
CME feeding. Although alcoholic fatty liver is a major risk
factor for advanced liver injuries such as steatohepatitis,Journal of Biomedicine and Biotechnology 11
ﬁbrosis, and cirrhosis [51], previous studies have mostly
focusedontheantilipogenicor-inﬂammatoryactivityalone,
but not in combination, of a compound and extracts. For
example,Kumaretal.evaluatedtheeﬀectoftheCassiaauric-
ulata leaf extract on lipid metabolism in alcohol-induced
hepatic steatosis [33]. Resveratrol prevents the development
of hepatic steatosis induced by alcohol, by restoring the
inhibited hepatic SIRT1-AMPK signaling system [70]. This
study demonstrated that both lipogenesis and inﬂammation
are associated with the development of alcoholic fatty liver
and that CME has both antilipogenic and anti-inﬂammatory
eﬀects through coordinated multiple signaling pathways.
Although much further study is required concerning the
exact identities of the chemical constituents of the C.
lanceolata methanol extract that are responsible for the
ﬁndings described herein, the results of this study provide
some insights on the basic mechanism that underlies the
therapeutic eﬀect of the extract on mice hepatic tissues after
chronic ethanol feeding.
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